GSTM1 and anemia (phenotype): Although there is considerable theoretical concern that increasing hemoglobin (Hb) level could accelerate the progression of renal dysfunction, several studies have demonstrated the safety and efficacy of r-HuEPO in the correction of anemia in predialysis patients, without causing a decline in renal function [6,7,8].